Bryan Cox
Direttore Tecnico/Scientifico/R&S presso TRISALUS LIFE SCIENCES, INC.
Patrimonio netto: 860 891 $ in data 30/04/2024
Profilo
Dr. Bryan F.
Cox is a Chief Scientific & Manufacturing Officer at TriSalus Life Sciences, Inc. and a Chief Executive Officer at Nephraegis Therapeutics, Inc.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 12/02/2024 | 86 696 ( 0.32% ) | 860 891 $ | 30/04/2024 |
Posizioni attive di Bryan Cox
| Società | Posizione | Inizio |
|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Direttore Tecnico/Scientifico/R&S | 10/08/2023 |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Health Technology |
- Borsa valori
- Insiders
- Bryan Cox